Highlights Pulse Biosciences, Inc.

Equities

PLSE

US74587B1017

Real-time Estimate Cboe BZX Other stock markets 01:44:29 2024-06-04 pm EDT			5-day change	1st Jan Change
14.76 ^USD	+8.61%		+8.63%	+18.22%

May. 20	Pulse Biosciences Moves New Record Date for Rights Offering	MT
May. 14	Pulse Biosciences Appoints Burke Barrett as President, CEO	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Pulse Biosciences, Inc. Announces First U.S. Procedure with the CellFX nsPFA Percutaneous Electrode System	May. 09	CI
Pulse Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 07	CI
Sector Update: Health Care Stocks Slide Late Afternoon	Apr. 01	MT
Pulse Biosciences Shares Fall After Q4 Results, Rights Issue Plans	Apr. 01	MT
Pulse Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
Pulse Biosciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 28	CI
Pulse Biosciences Gets FDA Clearance For Percutaneous Electrode System	Mar. 08	MT
Pulse Biosciences, Inc. Announces FDA 510(K) Clearance for its CellFX nsPFA Percutaneous Electrode System	Mar. 08	CI
Pulse Biosciences, Inc. Announces Positive 60-Day Follow-Up Evaluations for Initial Patients Treated in the Cellfx Nspfa 360° Cardiac Catheter First-In-Human Feasibility Study	Feb. 14	CI
Pulse Biosciences Files FDA Notification to Advance Testing of New Cardiac Clamp	Jan. 02	MT
Pulse Biosciences Files 510(K) Submission with U.S. FDA for its CellFX nsPFA Cardiac Clamp	Jan. 02	CI
Pulse Biosciences, Inc. Announces First-In-Human Procedures with its Novel CellFX Nanosecond Pulsed Field Ablation Cardiac Catheter	Dec. 20	CI
Pulse Biosciences Cleared to Start Catheter Ablation Feasibility Trial; Set to File Application for Cardiac Clamp; Shares Rise	Nov. 27	MT
Pulse Biosciences Shares Climb On Application for Percutaneous Electrode Review	Nov. 21	DJ
Pulse Biosciences, Inc. Announces Filing of Premarket Notification 510(k) to U.S. Food and Drug Administration for its Novel CellFX nsPFA Percutaneous Electrode	Nov. 21	CI
Pulse Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
Pulse Biosciences, Inc. Announces Collaboration with CardioNXT for nsPFA First-in-Human Atrial Fibrillation Study	23-10-02	CI
Pulse Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
Pulse Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11	CI
Pulse Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-10	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Pulse Biosciences, Inc.

Equities

PLSE

US74587B1017

Highlights

Filters